Biogen Inc
NASDAQ:BIIB 4:00:00 PM EDT
| Market Cap (Intraday) | 38.89B |
| Current PE | 13.13 |
| Forward PE | 17.07 |
| 2yr Forward PE | 16.21 |
| 10-Day MA | $264.50 |
| 50-Day MA | $276.95 |
| 200-Day MA | $252.07 |
Biogen Inc Stock, NASDAQ:BIIB
225 Binney Street, Cambridge, Massachusetts 02142
United States of America
Phone: +1.617.679.2000
Number of Employees: 8725
Description
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.